Table 4.
Serum lipid profile and plasma TAC in patients with prediabetes of the PLC and MO groups during the intervention.
| 0 Weeks | 6 Weeks | 12 Weeks | MIXED Model p # | Rate of Change 0 Weeks–12 Weeks a |
||
|---|---|---|---|---|---|---|
| Total Cholesterol (mg/dL) | PLC | 206.4 ± 36.4 | 207.7 ± 36.0 | 211.2 ± 34.6 | 0.494 | 0.033 ± 0.122 |
| MO | 197.9 ± 31.5 | 208.6 ± 29.1 | 203.1 ± 35.0 | 0.011 ± 0.123 | ||
| NS | ||||||
| TAG (mg/dL) | PLC | 102.2 ± 46.5 | 106.7 ± 43.2 | 113.0 ± 51.2 | 0.824 | 0.143 ± 0.352 |
| MO | 110.2 ± 43.3 | 115.82 ± 49.5 | 121.8 ± 72.8 | 0.110 ± 0.297 | ||
| NS | ||||||
| HDL-C (mg/dL) | PLC | 57.8 ± 12.0 | 59.6 ± 13.4 | 61.8 ± 15.0 | 0.608 | 0.073 ± 0.157 |
| MO | 57.8 ± 14.3 | 59.1 ± 14.7 | 58.9 ± 14.9 | 0.026 ± 0.176 | ||
| NS | ||||||
| LDL-C (mg/dL) | PLC | 128.1 ± 34.4 | 126.8 ± 33.2 | 126.7 ± 34.5 | 0.307 | 0.001 ± 0.155 |
| MO | 118.1 ± 27.9 | 126.4 ± 27.4 | 119.8 ± 30.0 | 0.000 ± 0.184 | ||
| NS | ||||||
| VLDL-C (mg/dL) | PLC | 20.4 ± 9.3 | 21.3 ± 8.6 | 22.7 ± 10.1 | 0.776 | 0.145 ± 0.349 |
| MO | 22.1 ± 8.5 | 23.1 ± 9.9 | 24.4 ± 14.6 | 0.096 ± 0.296 | ||
| NS | ||||||
| TAC | PLC | 1.34 ± 0.32 | 1.29 ± 0.37 | 1.30 ± 0.45 | 0.134 | −0.01 ± 0.32 |
| MO | 1.22 ± 0.42 | 1.27 ± 0.39 | 1.09 ± 0.44 | 0.03 ± 0.57 | ||
| NS | ||||||
Mean ± SD. MIXED linear model with the repeated factor “visit” and the fixed factors “treatment”, “Fat_Status” and “anti-hypercholesterolemic treatment” and the interaction “visit × treatment” and “visit × Fat_status”; p # corresponds to “visit × treatment”. a ANCOVA with the fixed factor “treatment”, the confounding factors “Fat_Status” and “anti-hypercholesterolemic treatment” and the basal value as covariate. TAG, triacylglycerides; NS, not significant. PLC: placebo; MO: Moringa oleifera Lam.